Separating Empty and Full Recombinant Adeno‐Associated Virus Particles Using Isocratic Anion Exchange Chromatography
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Separating Empty and Full Recombinant Adeno‐Associated Virus Particles Using Isocratic Anion Exchange Chromatography
Authors
Keywords
-
Journal
Biotechnology Journal
Volume -, Issue -, Pages 2000015
Publisher
Wiley
Online
2020-10-02
DOI
10.1002/biot.202000015
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adeno-associated viral vector serotype 9–based gene therapy for Niemann-Pick disease type A
- (2019) Lluis Samaranch et al. Science Translational Medicine
- Analytical Strategies for Quantification of Adeno-Associated Virus Empty Capsids to Support Process Development
- (2019) Xiaotong Fu et al. Human Gene Therapy Methods
- Developing an Anion Exchange Chromatography (AEX) Assay for Determining Empty and Full Capsid Contents in AAV6.2
- (2019) Chunlei Wang et al. Molecular Therapy-Methods & Clinical Development
- Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes
- (2018) Shelley A. Nass et al. Molecular Therapy-Methods & Clinical Development
- Helper-free Production of Laboratory Grade AAV and Purification by Iodixanol Density Gradient Centrifugation
- (2018) Sean M. Crosson et al. Molecular Therapy-Methods & Clinical Development
- Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy
- (2018) Yi Gong et al. HUMAN GENE THERAPY
- Comparative Analysis of Cesium Chloride- and Iodixanol-Based Purification of Recombinant Adeno-Associated Viral Vectors for Preclinical Applications
- (2015) Benjamin Strobel et al. Human Gene Therapy Methods
- Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates
- (2014) M A Kotterman et al. GENE THERAPY
- Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects
- (2014) Kai Gao et al. Molecular Therapy-Methods & Clinical Development
- Structure and Dynamics of Adeno-Associated Virus Serotype 1 VP1-Unique N-Terminal Domain and Its Role in Capsid Trafficking
- (2013) B. Venkatakrishnan et al. JOURNAL OF VIROLOGY
- Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
- (2013) F. Mingozzi et al. Science Translational Medicine
- Analysis of Particle Content of Recombinant Adeno-Associated Virus Serotype 8 Vectors by Ion-Exchange Chromatography
- (2012) Martin Lock et al. Human Gene Therapy Methods
- High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency
- (2009) E Ayuso et al. GENE THERAPY
- Scalable Purification of Adeno-associated Virus Serotype 1 (AAV1) and AAV8 Vectors, Using Dual Ion-Exchange Adsorptive Membranes
- (2009) Takashi Okada et al. HUMAN GENE THERAPY
- Scalable Recombinant Adeno-Associated Virus Production Using Recombinant Herpes Simplex Virus Type 1 Coinfection of Suspension-Adapted Mammalian Cells
- (2009) Darby L. Thomas et al. HUMAN GENE THERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started